LL-37 vs Vladonix
Overview
LL-37 is primarily a pain management peptide, while Vladonix is used for immune support.
This page compares LL-37 and Vladonix across their primary use, typical dosing, reported benefits and side effects, and U.S. regulatory status. For the full monograph on either compound — mechanism of action, clinical research, and references — follow the article links.
Side-by-side comparison
| LL-37 | Vladonix | |
|---|---|---|
| Category | Pain Management | Immune Support |
| Regulatory status (US) | Compounding (Rx) — Apr 2026 | Research use only |
| Typical dosage | 2-5 mg | 10 mg |
| Frequency | twice weekly | daily for cycles |
| Reported benefits | Inflammation-related pain relief, infection-related pain support | Immune system balance, T-cell production support, longevity |
| Reported side effects | Generally safe | Generally well-tolerated |
Key differences
Primary use. LL-37 is categorised under Pain Management, while Vladonix falls under Immune Support. Their differing categories mean they are usually chosen for different goals rather than as direct substitutes.
Regulatory status. LL-37: not FDA-approved; compounding permitted with a prescription as of April 2026. Vladonix: not FDA-approved; treated as a research compound.
Dosing. LL-37 is typically dosed at 2-5 mg (twice weekly). Vladonix is typically dosed at 10 mg (daily for cycles).
Can you stack them?
Some protocols combine peptides, but stacking LL-37 and Vladonix has not been validated for safety or efficacy in controlled trials. Combining compounds can change their effects and risks. Nothing here is medical advice — consult a qualified healthcare provider before starting or combining any protocol.
Frequently asked questions
- What is the difference between LL-37 and Vladonix?
- LL-37 is primarily a pain management peptide, while Vladonix is used for immune support. LL-37 is not FDA-approved; compounding permitted with a prescription (as of April 2026), whereas Vladonix is not FDA-approved; generally classified as a research compound.
- What is LL-37 used for?
- Inflammatory pain modulation.
- What is Vladonix used for?
- Thymus bioregulator complex.
- Can you take LL-37 and Vladonix together?
- Some users combine peptides within a single protocol, but stacking LL-37 and Vladonix has not been established as safe or effective in controlled trials. Neither this comparison nor PeptideSciences101 is medical advice — consult a qualified healthcare provider before combining any compounds.
- Is LL-37 or Vladonix FDA-approved?
- LL-37 is not FDA-approved; compounding permitted with a prescription (as of April 2026). Vladonix is not FDA-approved; generally classified as a research compound.